Illumina CEO Says Firm Has No Plans to Exit Array Market as Chips, NGS Remain 'Highly Complementary' | GenomeWeb

NEW YORK (GenomeWeb) — Illumina may be the dominant microarray vendor but that hasn't stopped some from pondering the future of its BeadChip business given the San Diego company's focus on next-generation sequencing.

During a presentation at Bank of America Merrill Lynch's Healthcare Conference in Las Vegas last week, analysts asked CEO Jay Flatley about Illumina's intentions for its array business, which continues to register single-digit quarterly growth even as it has been overshadowed by Illumina's activities in the sequencing market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.